The Taskforce also told us that the COVID-19 vaccine market was still developing and that it considered many different factors when deciding which vaccines to procure, including the evolution of the virus and improved learning about different types of vaccines and how they work.48 The Taskforce was confident that the Pfizer and Moderna vaccines remained the most effective choice for boosters and that they would provide access to reformulations against emerging variant viruses if and when requ...

The Taskforce also told us that the COVID-19 vaccine market was still developing and that it considered many different factors when deciding which vaccines to procure, including the evolution of the virus and improved learning about different types of vaccines and how they work.48 The Taskforce was confident that the Pfizer and Moderna vaccines remained the most effective choice for boosters and that they would provide access to reformulations against emerging variant viruses if and when required.49 We note that the approval of the Valneva vaccine happened after the UK government cancelled its contract with Valneva.50 The Taskforce had previo Type: conclusion | Number: 21 | Response status: not_addressed Government response: 5: PAC conclusion: After starting with a portfolio of seven candidates, the UK’s vaccine supply for 2022 and 2023 now relies primarily on just two, yet many of the risks that the ‘portfolio’ approach was intended to mitigate remain. 5: PAC recommendation: The Dep